Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Harrow Health ( (HROW) ) just unveiled an announcement.
On March 24, 2026, Harrow announced it had priced a $50 million private offering of 8.625% senior unsecured notes due 2030, to be issued as additional notes under the same indenture as its existing $250 million 2030 notes sold in September 2025. The new notes, guaranteed on a senior unsecured basis by certain current and future subsidiaries, are expected to close on March 27, 2026, subject to customary conditions.
The additional 2030 notes will form a single series with the existing issue, bearing the same 8.625% coupon, maturing on September 15, 2030, and carrying interest deemed accrued from March 15, 2026, with semiannual payments starting September 15, 2026. Issued at 100.25% of par plus accrued interest and sold only to qualified institutional buyers and certain non-U.S. investors, the deal expands Harrow’s fixed-income capital base, with net proceeds earmarked for general corporate purposes including growth initiatives, product development and strategic business opportunities.
The most recent analyst rating on (HROW) stock is a Sell with a $32.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
The score is held back primarily by high leverage and weak/uncertain cash flow quality, alongside bearish technicals with the stock trading below major moving averages. Offsetting these risks, the latest earnings call was notably positive with strong 2025 execution and robust 2026 revenue/adjusted EBITDA guidance, but valuation support is limited given the negative P/E and no dividend.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Harrow, Inc., based in Nashville and listed on Nasdaq as HROW, is a leading North American provider of ophthalmic disease management solutions. The company offers a broad portfolio of medications for conditions affecting the front and back of the eye, including dry eye disease, neovascular age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface disorders and retina diseases.
Founded with a focus on safety, effectiveness, accessibility and affordability, Harrow aims to improve patient compliance and clinical outcomes through its specialty eye-care therapies. Its market positioning centers on comprehensive coverage of key ophthalmic indications, targeting both common and complex vision-threatening conditions across the region.
Average Trading Volume: 748,834
Technical Sentiment Signal: Hold
Current Market Cap: $1.27B
For a thorough assessment of HROW stock, go to TipRanks’ Stock Analysis page.